Efficacy and safety of Sertraline treatment of posttraumatic stress disorder. Journal of the American Medical Association, 283, 1837-1844. Calabrese, J. R., Kimmel, S. E., Woyshville, M. J., Rapport, D. J., Faust, C. J., Thompson, P. A., & Meltzer, H. Y. (1996). Clozapine for treatment-refractory mania. American Journal of Psychiatry, 153, 759-764. Daubert v. Merrell Dow Pharmaceuticals, Inc. (1993). 113S, Ct. 2786. Davidson, J., Rothbaum, B. O., Tucker, P., Asnis, G., Benattia, I., & Musgnung, J. J. (2006a). Venlafaxine extended release in post traumatic stress disorder: A Sertraline-and placebo-controlled study. Journal of Clinical Psychopharmacology, 26, 259-267. Davidson, J., Baldwin, D., Stein, D. J., Kuper, E., Benattia, I., Ahmed, S., Pedersen, R., & Musgnung, J. (2006b). Treatment of post traumatic stress disorder with Venlafaxine extended release. Archives of General Psychiatry, 63, 1158-1165. El-Mallakh, R. S., & Karippot, A. (2002). Use of antidepressants to treat depression in bipolar disorder. Psychiatric Services, 53, 580-584. Gelenberg, A. J., Lydiard, R. B., Rudolph, R. L., Aguiar, L., Haskins, J. T., & Salinas, E. (2000). Efficacy of Venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder. Journal of the American Medical Association, 283, 3082-3088. Geller, D. A., Biederman, J., Reed, E. D., Spencer, T., & Wilens, T. E. (1995). Similarities in response to Fluoxetine in the treatment of children and adolescents with obsessive-compulsive disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 36-44. Ghaemi, S. N., Sachs, G. S., Chiou, A. M., Pandurangi, A. K., & Goodwin, F. K. (1999). Is bipolar disorder still underdiagnosed? Are antidepressants overutilized? Journal of Affective Disorders, 52, 135-144. Hoehn-Saric, R., Ninan, P., Black, D. W., Stahl, S., Greist, J. H., Lydiard, B., McElroy, S., Zajecka, J., Chapman, D., Clary, C., & Harrison, W. (2000). Multicenter double-blind comparison of Sertraline and Desipramine for concurrent obsessive-compulsive and major depressive disorders. Archives of General Psychiatry, 57, 76-82. Hurt, R. D., Sachs, D. P. L., Glover, E. D., Offord, K, P., Johnston, J. A., Dale, L. C., Khayrallah, M. A., Schroeder, D. R., Glover, P. N., Sullivan C. R., Crogham, I. T., & Sullivan, P. M. (1997). A comparison of sustained-release Bupropion and placebo for smoking cessation. New England Journal of Medicine, 337, 1195-1202. Jagadheesan, K., & Muirhead, D. (2004). Aripiprazole for acute bipolar mania. American Journal of Psychiatry, 161, 1926-1927. (Letter to the Editor). Keck, P. E., Marcus, R., Tourkodimitris, S., Ali, M., Liebeskind, A., Saha, A., Ingenito, G., and the Aripiprazole study group. (2003a). A placebo-controlled, doubleblind study of the efficacy and safety of Aripiprazole in patients with acute bipolar mania. American Journal of Psychiatry, 160, 1651-1658. Keck, P. E., Versiani, M., Potklin, S., West, S. A., Giller, E., Ice, K., and the Ziprasidone in mania study group. (2003b). Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, doubleblind, randomized trial. American Journal of Psychiatry, 160, 741-748. Lydiard, R. B., Steiner, M., Burnham, D., & Gergel, I. (1998). Efficacy studies of Paroxetine in panic disorder. Psychopharmacology Bulletin, 34, 175-182. Moreira-Almeida, A., & Pietrobon, R. (2006). Does Olanzapine have any antidepressant effect? American Journal of Psychiatry, 163, 1838-1839. Nickel, M. K., Muehlbacher, M., Nickel, C., Kettler, C., Gil, F. P., Bachler, E., Buschmann, W., Rother, N., Fartacek, R., Egger, C., Anvar, J., Rother, W. K., Loew, T. H., & Kaplan, P. (2006). Aripiprazole in the treatment of patients with borderline personality disorder: A
20 THE FORENSIC EXAMINER® Spring 2009
double-blind, placebo-controlled study. American Journal of Psychiatry, 163, 833-838. Papp, L. A., Sinha, S. S., Martinez, J. M., Coplan, J. D., Amchin, J., & Gorman, J. M. (1997). Low-dose Venlafaxine treatment in panic disorder. Psychopharmacology Bulletin, 34, 207-209. Piccinelli, M., Pini, S., Bellantuono, C., & Wilkinson, G. (1995). Efficacy of drug treatment in obsessive-compulsive disorder: A meta-analytic review. British Journal of Psychiatry, 166, 424-443. Rast, P. H. (2006). The Daubert decision: Accident reconstruction considerations. The Forensic Examiner, 15, 37-41. Saxena, S., Brody, A. L., Ho, M. L., Alborzian, S., Maidment, K. M., Zohrabi, N., Ho, M. K., Huang, S-C., Wu, H-M., & Baxter Jr., L. R. (2002). Differential cerebral metabolic changes with Paroxetine treatment of obsessive-compulsive disorder vs major depression. Archives of General Psychiatry, 59, 250-261. Schmidt, A. W., Lebel, L. A., Howard, H. R., & Zorn, S. H. (2001). Ziprasidone: A novel antipsychotic agent with a unique human receptor binding profile. European Journal of Pharmacology, 425, 197-201 (Abstract). Spencer, T., Biederman, J., Wilens, T., Harding, M., O’Donnell, D., & Griffin, S. (1996). Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 409-432. Spencer, T., Biederman, J. Coffey, B., Geller, D., Crawford, M., Bearman, S. K., Tarazi, R., & Faraone, S. V. (2002). A double-blind comparison of Desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Archives of General Psychiatry, 59, 649-656. Tohen, M., Sanger, T. M., McElroy, S. L., Tollefson, G. D., Chengappa, K. N. R., Daniel, D. G., Petty, F., Centorrino, F., Wang, R., Grundy. S. L., Greaney, M. G., Jacobs, T. G., David, S. R., Toma, V. and the Olanzapine HGEH study group. (1999). Olanzapine versus placebo in the treatment of acute mania. American Journal of Psychiatry, 156, 702-709. Tohen, M., Jacobs, T. G., Grundy, S. L., McElroy, S. L., Banov, M. C., Janicak, P. G., Sanger, T., Risser, R., Zhang, F., Toma, V., Francis, J., Tollefson, G. D., Breier, A. for the Olanzapine HGGW study group. (2000). Efficacy of Olanzapine in acute bipolar mania. Archives of General Psychiatry, 57, 841-849. Tohen, M., Zhang, F., Taylor, C. C., Burns, P., Zarate, C., Sanger, T., & Tollefson, G. (2001). A meta-analysis of the use of typical antipsychotic agents in bipolar disorder. Journal of Affective Disorders, 65, 85-93. (Abstract). Tohen, M., Chengappa, K. N. R., Suppes, T., Zarate, C. A., Calabrese, J. R., Bowden, C. L., Sachs, G. S., Kupfer, D. J., Baker, R. W., Risser, R. C., Keeter, E. L., Feldman, P. D., Tollefson, G. D., & Breier, A. (2002).
Efficacy of Olanzapine in combination with Valproate or Lithium in the treatment of mania in patients partially nonresponsive to Valproate or Lithium monotherapy. Archives of General Psychiatry, 59, 62-69. Tohen, M., Vieta, E., Calabrese, J., Ketter, T. A., Sachs, G., Bowden, C., Mitchell, P. B., Centorrino, F., Risser, R., Baker, R. W., Evans, A. R., Beymer, K., Dube, S., Tollefson, G. D., & Breier, A. (2003). Efficacy of Olanzapine and Olanzapine-Fluoxetine combination in the treatment of bipolar 1 depression. Archives of General Psychiatry, 60, 1079-1088. Wilens, T. E., Bieman, J., Prince, J., Spencer, T. J., Faraone, S. V., Warburton, R., Schleifer, D., Harding, M., Linehan, C., & Geller, D. (1996). Six-week, double-blind, placebo-controlled study of Desipramine for adult attention deficit hyperactivity disorder. American Journal of Psychiatry, 153, 1147-1153. Zanarini, M. C. & Frankenburg, F. R. (2001). Olanzapine treatment of female borderline personality disorder patients: A double-blind, placebo-controlled pilot study. Journal of Clinical Psychiatry, 62, 849-854. n
Earn CE Credit To earn CE credit, complete the exam for this article on page 21 or complete the exam online at www.acfei.com (select “Online CE”).
About the Author Dr. Sherwood Cole received his MA from UCLA and a PhD in Psychology from Claremont Graduate University. He is Professor Emeritus of Psychology at Rutgers University and taught Clinical Psychopharmacology on a part-time basis at Rosemead School of Psychology, Biola University for 8 years. In addition to teaching at the graduate-school level for more than 30 years, he has published extensively on the neural mechanisms and behavioral effects of psychotropic drugs. He is a member of the Society for Neuroscience, a member of the American Psychological Association (Division 28-Psychopharmacology and Substance Abuse), a Fellow of the Royal Society of Health in England, a Fellow of the American College of Forensic Examiners Institute, as well as a Diplomate of the American Board of Psychological Specialties (specialty in psychopharmacology). www.acfei.com